Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in Italy (DOMINO)
Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in the Italian Clinical Practice: a Retrospective Cohort, Observational Study
Sponsor: Otsuka Pharmaceutical Europe Ltd
This observational or N/A phase trial investigates Schizophrenia and is currently completed. Otsuka Pharmaceutical Europe Ltd leads this study, which shows 9 recorded versions since 2016 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 4 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Completed NA
Status: Recruiting → Completed
-
Feb 2017 — Aug 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Otsuka Pharmaceutical Europe Ltd
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ancona, Italy , Brescia, Italy , Cagliari, Italy , Catania, Italy , Catanzaro, Italy , Florence, Italy , Genzano di Roma, Italy , Giulianova, Italy , Lecce, Italy , Milan, Italy and 9 more locations